EP4701646A1 - Anti-ngf-impfstoffzusammensetzung - Google Patents

Anti-ngf-impfstoffzusammensetzung

Info

Publication number
EP4701646A1
EP4701646A1 EP24726940.0A EP24726940A EP4701646A1 EP 4701646 A1 EP4701646 A1 EP 4701646A1 EP 24726940 A EP24726940 A EP 24726940A EP 4701646 A1 EP4701646 A1 EP 4701646A1
Authority
EP
European Patent Office
Prior art keywords
subunit
sequence
ngf protein
ngf
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24726940.0A
Other languages
English (en)
French (fr)
Inventor
Jean-François ZAGURY
Hervé DO
Aïda MASCRET
Jean-Pierre Salles
René AZOULAI
Gabriel MOREAU
Florent LANGENFELD
Lucille DESALLAIS
Hadley Mouhsine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CNAM Conservatoire National des Arts et Metiers
Peptinov SAS
Original Assignee
CNAM Conservatoire National des Arts et Metiers
Peptinov SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CNAM Conservatoire National des Arts et Metiers, Peptinov SAS filed Critical CNAM Conservatoire National des Arts et Metiers
Publication of EP4701646A1 publication Critical patent/EP4701646A1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
EP24726940.0A 2023-04-24 2024-04-24 Anti-ngf-impfstoffzusammensetzung Pending EP4701646A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2304118A FR3148027A1 (fr) 2023-04-24 2023-04-24 Composition vaccinale anti-ngf
PCT/EP2024/061328 WO2024223713A1 (fr) 2023-04-24 2024-04-24 Composition vaccinale anti-ngf

Publications (1)

Publication Number Publication Date
EP4701646A1 true EP4701646A1 (de) 2026-03-04

Family

ID=89574029

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24726940.0A Pending EP4701646A1 (de) 2023-04-24 2024-04-24 Anti-ngf-impfstoffzusammensetzung

Country Status (7)

Country Link
EP (1) EP4701646A1 (de)
KR (1) KR20260040522A (de)
CN (1) CN121666242A (de)
AU (1) AU2024261873A1 (de)
FR (1) FR3148027A1 (de)
IL (1) IL324224A (de)
WO (1) WO2024223713A1 (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60123399T2 (de) * 2000-01-18 2007-08-23 The Texas A & M University System, College Station Pharmazeutische zubereitungen enthaltend beta-turn peptidomimetische zyklische substanzen
KR100894191B1 (ko) * 2003-07-15 2009-04-22 암젠 인코포레이티드 선택적인 ｎｇｆ 경로 저해제로서의 인체 항-ｎｇｆ 중화 항체 및 이 항체를 포함하는 약학적 조성물
AU2016247195A1 (en) * 2003-07-15 2016-11-10 Amgen Inc. Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
CN102408483B (zh) * 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
US20080019991A1 (en) 2004-06-02 2008-01-24 Cytos Biotechnology Ag Carrier Conjugates Of Tnf-Peptides
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same

Also Published As

Publication number Publication date
AU2024261873A9 (en) 2025-12-04
KR20260040522A (ko) 2026-03-24
AU2024261873A1 (en) 2025-11-27
WO2024223713A1 (fr) 2024-10-31
IL324224A (en) 2025-12-01
CN121666242A (zh) 2026-03-13
FR3148027A1 (fr) 2024-10-25

Similar Documents

Publication Publication Date Title
EP2812020B1 (de) 28 kda-gst-proteine aus schistosoma zur behandlung von entzündlichen autoimmunkrankheiten mit erzeugung einer th1- und/oder th17-reaktion
JP7208965B2 (ja) Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
von Loga et al. Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis
FR2807660A1 (fr) Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
KR20110036809A (ko) 파킨슨병과 관련된 증상을 치료하기 위한 화합물
JP2009531294A (ja) 抗アミロイド免疫原性組成物、方法、および使用
WO2019170686A1 (fr) Composition vaccinale anti-pd-l1
FR2823221A1 (fr) Sequences associees a la degenerescence retinienne et applications
FR2978964A1 (fr) Composition vaccinale anti-il-6
JP2005519033A (ja) オステオポンチン関連組成物および方法
EP4701646A1 (de) Anti-ngf-impfstoffzusammensetzung
WO2019170684A1 (fr) Composition vaccinale anti-pd-1
CA3163270A1 (fr) Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires
US20240358806A1 (en) Methods for the prevention and treatment of synucleinopathies
CA3209309A1 (fr) Vaccin pour un traitement therapeutique ou prophylactique de la myastenie grave
WO2002035242A1 (fr) Procede d'identification de nouvelles molecules se liant au recepteur lox
CA3163277A1 (fr) Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l'interleukine-6
AU2024293770A1 (en) Active immunization for treating atopic dermatitis
US9301997B2 (en) Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides
JP2022131943A (ja) ワクチン、医薬及び糖尿病合併症治療薬
WO2019121966A1 (fr) Composition pharmaceutique pour administration orale d'anticorps pour le traitement des maladies du tractus gastro-intestinal
WO2003041732A2 (fr) Compositions vaccinales contraceptives comprenant des peptides codes par un recepteur de la fsh

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR